Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Massive Bio logo — AI-driven system connecting cancer patients to clinical tria...

Massive Bio

AI-driven system connecting cancer patients to clinical trials in real time. Industrializing the oncology action layer.

Founded 2019 Turkey Turkey 103 employees Series B Total: $28.10M AI, Big Data +5

General Information

Company Name Massive Bio
Founded Year 2019
Location Turkey Turkey
Founders / Decision Makers
Team member Team member Team member
Employees 103
Industries AI, Big Data, Biotechnology +4
Funding Stage Series B
Business Model B2B, B2C, Platform
Revenue Model Service Fee, Performance Based, Subscription
Hiring 18 roles posted in the month to 29 Oct 2026
Offices as of Sep 2026
Istanbul, Turkey Boca Raton, United States
Social

BounceWatch is an independent company data service, not affiliated with Massive Bio. To contact Massive Bio, visit massivebio.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Massive Bio compare?

A PDF of Massive Bio and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Massive Bio soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

Recorded by Bounce Watch from public sources. Every entry below carries the date we observed it, and when we have not looked recently the page says so rather than leaving silence to imply nothing happened.

Actively Hiring Oct 24, 2026

Hiring for 19 positions in the last 30 days.

Event Participation Oct 21, 2026

Massive Bio is discussing exciting AI in breast cancer data at the upcoming ESMO - European Society for Medical Oncology 2026 event.

Partnership Talks Oct 15, 2026

Massive Bio is holding discussions with Moffitt clinical and research teams regarding a potential collaboration on AI-powered prescreening and clinical trial matching.

New Partnership Oct 14, 2026

Massive Bio announced a partnership with Meta, St. Luke's University Health Network, Dana-Farber Cancer Institute, Stanford University School of Medicine, and University of Washington on a project …

Raising Funds Oct 11, 2026

Massive Bio indicates fundraising intent through its CEO's engagement with investors and by stating the company continues to grow and build with more updates on the way.

LinkedIn Growth Oct 07, 2026

LinkedIn followers decreased by 76% over 29 days (46,621 → 11,364).

Get alerts when Massive Bio shows new signals

AI Insight

Bounce Watch AI
1 month ago

Massive Bio is exhibiting robust strategic growth, evidenced by a significant nation-wide partnership with the American Cancer Society and the formal positioning of its comprehensive "clinical follow-through infrastructure" AI platform. This strong momentum is further validated by its recognition as an early adopter of the CMS Clinical Trial Matching pledge, signaling a commitment to broader market reach and enhanced industry integration for its AI-driven oncology solutions. These developments highlight a strategic push to scale their impact and solidify their leadership in revolutionizing clinical trial access.

Signal Types
Partnership Product Launch Recognition
Strategic Labels
Market Expansion AI Platform Scaling Industry Validation
Next Move: Expansion
·
Impact: 9/10
·
Ideal For: Growth Stage Digital Health Investors — Series B+

About Massive Bio

Massive Bio, founded in 2014, is revolutionizing the oncology sector with its AI-driven system that connects cancer patients to clinical trials in real-time, thereby industrializing the oncology action layer. Operating in 17 countries across North America, Europe, and LATAM, this Turkey-headquartered company is at the forefront of ensuring equitable trial access using proprietary AI technology.

With an extensive network, Massive Bio has onboarded over 200K patients and developed partnerships with 60+ pharmaceutical and CRO customers, as well as 130+ strategic partners. Its collaboration with the White House’s Cancer Moonshot underscores its industry influence.

The company’s latest $16.50M Series B funding on 01 December 2022 involved investors including Revo Capital, ImpactAssets, and Toyota Financial Services. With its focus on reducing dropout rates and delivering real-world evidence, Massive Bio represents a compelling investment opportunity in the intersection of AI and biotechnology.

Business keywords: AI-driven oncology solutions, Clinical trial matching, Oncology trial enrollment, Real-world evidence, Precision oncology, Neurosymbolic systems, Patient enrollment optimization, Cancer genomics, Tumor profiling technologies, Drug development acceleration, Virtual site activation, Personalized cancer treatment, Patient support services, Cancer research partnerships, Healthcare technology innovation

Services & Products

AI-driven clinical trial matching
Cancer patient support
Tailored medical reports
Financial assistance exploration
Insurance coverage review

Target Customers

Cancer patients Physicians Healthcare providers Pharmaceutical companies Clinical researchers

Funding Rounds & Investors (7)

View All
Funding Stage Amount Investors Lead Investors Date
Series B $16.50M 7
Revo Capital ImpactAssets International Finance Corporation
Revo Capital, ImpactAssets +5
01 Dec 2022
Early VC $9.00M 3
Revo Capital
Revo Capital, German Investment Corporation +1
01 Jun 2022
Seed $2.60M 2
Revo Capital Cavendish Impact Capital
Revo Capital, Cavendish Impact Capital
01 Nov 2020
Seed Undisclosed 1
UL Ventures
UL Ventures
01 May 2019
Early VC Undisclosed 1
UL Ventures
UL Ventures
01 Jul 2018
Seed Undisclosed 1
Arturo Loaiza-Bonilla
01 Jul 2016
Convertible Note Undisclosed 1
500 Global
01 Apr 2015

Latest News

View All
TIME Recognizes Massive Bio Among the Top HealthTech Companies in AI and Data Analytics — Kitsap Sun
TIME Recognizes Massive Bio Among the Top HealthTech Companies in AI and Data Analytics
Kitsap Sun Sep 29, 2026
Chennai Reclaims 100.29 Acres Through Massive Bio-Mining Drive — Livechennai.com
Chennai Reclaims 100.29 Acres Through Massive Bio-Mining Drive
Livechennai.com Dec 11, 2025
Massive Bio Collaborates with the American Cancer Society to Accelerate Equitable Access to Cancer C... — Businesswire.com
Massive Bio Collaborates with the American Cancer Society to Accelerate Equitable Access to Cancer Clinical Trials
Businesswire.com Nov 18, 2025
Massive Bio Announces Reticulum Nexus - an AI-Driven Multi Agent Platform orchestrating the end-to-e... — Fox5sandiego.com
Massive Bio Announces Reticulum Nexus - an AI-Driven Multi Agent Platform orchestrating the end-to-end patient journey
Fox5sandiego.com Nov 14, 2025
Zimbabwe targets massive bio-diesel production — Heraldonline.co.zw
Zimbabwe targets massive bio-diesel production
Heraldonline.co.zw Sep 29, 2025
Revo Capital, Midas’tan kısmi çıkış yaptı — Forbes.com.tr
Revo Capital, Midas’tan kısmi çıkış yaptı
Forbes.com.tr Sep 01, 2025

Massive Bio Alternatives & Competitors

View All Alternatives
Massive Bio vs
NBE-Therapeutics AG
NBE-Therapeutics AG Switzerland

Next generation antibody drug conjugates

Series C
48 employees
Biotechnology, Health Care
Compare Massive Bio vs NBE-Therapeutics AG
Massive Bio vs
Hyfe
Hyfe United States

AI-powered cough-tracking & insights. Precision medicine for respiratory health

Seed
44 employees
AI, Health Care
Compare Massive Bio vs Hyfe
Massive Bio vs
Franklin by QIAGEN
Franklin by QIAGEN United States

Franklin harnesses the power of its community to enable actionable insights, serving professionals a...

Acquired
53 employees
AI, Biotechnology
Also compare with: Massive Bio vs Ancora.ai Ancora.ai View all alternatives

FAQ About Massive Bio

AI-driven system connecting cancer patients to clinical trials in real time. Industrializing the oncology action layer.
Massive Bio was founded in 2019.
Massive Bio is headquartered in Turkey. As of Sep 2026, it also has offices in Istanbul, Turkey and Boca Raton, United States.
Massive Bio operates in AI, Big Data, Biotechnology, Health Care, Health and Wellness, Pharmaceutical and Machine Learning. Its work centres on AI-driven oncology solutions, Clinical trial matching, Oncology trial enrollment and Real-world evidence. Its customers include Cancer patients, Physicians and Healthcare providers.
Massive Bio has a B2B, B2C and Platform business model. Its revenue comes from Service Fee, Performance Based and Subscription.
Massive Bio has approximately 103 employees.
Massive Bio has completed 7 funding rounds, raising a total of $28.10M. The latest funding stage is Series B.
Massive Bio offers: AI-driven clinical trial matching, Cancer patient support, Tailored medical reports, Financial assistance exploration, Insurance coverage review.
Top alternatives and competitors to Massive Bio include NBE-Therapeutics AG, Hyfe, Franklin by QIAGEN, Ancora.ai, Adcentrx Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Massive Bio and NBE-Therapeutics AG are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Massive Bio, https://bouncewatch.com/company/massive-bio-1, updated 12 October 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes